Guangdong Biolight Meditech Co., Ltd. (300246.SZ) Latest Company News

Oct 14, 2026, 08:27 UTC
The National Medical Products Administration granted BaoLaiTe a Class III medical device registration certificate for its G-series patient monitor, valid through October 8, 2031.
Source:
- finance.sina.cn
Oct 13, 2026, 10:04 UTC
Baolait announced that plaintiffs including Suzhou Junying Industrial Investment Partnership (Limited Partnership) filed a contract-dispute lawsuit against it and sought asset preservation, resulting in RMB 64.4 million being frozen in one of its bank accounts.
Source:
- finance.sina.cn
Sep 22, 2026, 02:45 UTC
Biolight and other investors jointly established Quzhou Baowei Zhichun Technology Co., Ltd., a new technology company whose business scope includes AI software development, IoT technology R&D, and integrated circuit design and chip sales.
Source:
- finance.sina.cn
Sep 18, 2026, 09:18 UTC
Biolight completed the industrial and commercial registration of its joint venture Bao Wei Zhi Cun, established on September 16, 2026, with registered capital of RMB 200 million, of which Biolight contributed RMB 150 million for a 75% stake.
Source:
- finance.sina.cn
Aug 21, 2026, 08:41 UTC
Baolait announced its H1 2026 results: net loss of 34.4869 million yuan, turning from a profit of 1.3134 million yuan in the same period of 2025.
Source:
- finance.sina.cn
Aug 19, 2026, 13:49 UTC
On August 19, 2026, three A-share listed companies, including Baolait, Zhongjiao Design, and Huaxin Building Materials, disclosed plans to increase their holdings.
Source:
- finance.sina.cn
Aug 9, 2026, 07:36 UTC
Baolait terminated the planning of a control change matter; its stock and convertible bonds resumed trading on August 10, 2026.
Source:
- finance.sina.cn
Aug 4, 2026, 09:01 UTC
Baolait announced on August 4, 2026 that it will close or partially terminate certain fundraising investment projects and use the remaining 60.6631 million yuan to permanently supplement working capital, pending shareholder approval.
Source:
- finance.sina.cn
Jul 23, 2026, 10:08 UTC
Baolait announced it received a medical device registration certificate from the National Medical Products Administration for its blood purification equipment, models Elix-Ω and Elix-90, valid until July 15, 2031.
Source:
- finance.sina.cn

300246.SZ

The National Medical Products Administration granted BaoLaiTe a Class III medical device registration certificate for its G-series patient monitor, valid through October 8, 2031.

Baolait announced that plaintiffs including Suzhou Junying Industrial Investment Partnership (Limited Partnership) filed a contract-dispute lawsuit against it and sought asset preservation, resulting in RMB 64.4 million being frozen in one of its bank accounts.

Biolight and other investors jointly established Quzhou Baowei Zhichun Technology Co., Ltd., a new technology company whose business scope includes AI software development, IoT technology R&D, and integrated circuit design and chip sales.

Biolight completed the industrial and commercial registration of its joint venture Bao Wei Zhi Cun, established on September 16, 2026, with registered capital of RMB 200 million, of which Biolight contributed RMB 150 million for a 75% stake.

Baolait announced its H1 2026 results: net loss of 34.4869 million yuan, turning from a profit of 1.3134 million yuan in the same period of 2025.

On August 19, 2026, three A-share listed companies, including Baolait, Zhongjiao Design, and Huaxin Building Materials, disclosed plans to increase their holdings.

Baolait terminated the planning of a control change matter; its stock and convertible bonds resumed trading on August 10, 2026.

Baolait announced on August 4, 2026 that it will close or partially terminate certain fundraising investment projects and use the remaining 60.6631 million yuan to permanently supplement working capital, pending shareholder approval.

Baolait announced it received a medical device registration certificate from the National Medical Products Administration for its blood purification equipment, models Elix-Ω and Elix-90, valid until July 15, 2031.